This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Asia
20 - 22 October, 2025
Presented in Japan Standard TimeThe Westin Miyako Kyoto

Delivered as a Hybrid Event

Dr. Stefan Warmuth, PhD
SVP, Head Technology and CMC at Numab Therapeutics AG
Speaker

Profile

Stefan is heading discovery and CMC activities at Numab as well as technology projects. This includes antibody discovery, protein engineering, analytics, and formulation, USP and DSP development. He is responsible for the CMC strategy and oversees the manufacturing activities of the international network of external CMOs. Stefan studied biochemistry in Tübingen and Zurich and graduated with a degree in Biochemistry from the ETH Zurich and obtained his PhD in Structural Biology and Biochemistry from the University of Zurich.

Agenda Sessions

  • Multispecific Antibodies Application for Inflammation and Oncology - Design and Clinical Outcomes

    14:00